Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01162239 · ClinicalTrials.gov registry record · Phase 3
Maintaining Nonsmoking
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT01162239 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 216 participants.
The verdict
NCT01162239, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
The research is based on a chronic disorder model of cigarette smoking which suggests that long-term treatment targeted to prevent relapse may be useful. Based on this model, the investigators have developed a relapse prevention treatment to intervene on five areas important in relapse prevention, including fluctuating motivation, depression, withdrawal, weight gain, and social support. This treatment protocol has produced high long-term abstinence rates when implemented in a clinical research setting. The current study will evaluate the treatment model when implemented in a medical outpatient setting.
Interventions
- DRUG Varenicline
- BEHAVIORAL Initial Individual counseling
- BEHAVIORAL Check-ins with medical staff
- BEHAVIORAL Extended Individual Counseling - Health Model
- BEHAVIORAL Extended Individual Counseling - Relapse Prevention Model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2010-05 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01162239
The ClinicalTrials.gov registry entry for NCT01162239 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Varenicline is the first listed.
NCT01162239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01162239 about?
NCT01162239 is a clinical study titled "Maintaining Nonsmoking". The research is based on a chronic disorder model of cigarette smoking which suggests that long-term treatment targeted to prevent relapse may be useful. Based on this model, the investigators have developed a relapse prevention treatment to intervene on five areas important in relapse prevention, i...
What is the current status of trial NCT01162239?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2010-05. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01162239?
The interventions under investigation include: Varenicline (DRUG), Initial Individual counseling (BEHAVIORAL), Check-ins with medical staff (BEHAVIORAL), Extended Individual Counseling - Health Model (BEHAVIORAL), Extended Individual Counseling - Relapse Prevention Model (BEHAVIORAL).
Who is sponsoring clinical trial NCT01162239?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.